Screener
Castle Biosciences CSTL Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Total assets | $547,805 | $578,556 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities | ||
| Accounts payable | $15,038 | $18,711 |
| Accrued compensation | 19,111 | 38,287 |
| Contingent consideration | 1,000 | 1,000 |
| Operating lease liabilities | 1,254 | 1,325 |
| Current portion of long-term debt | 1,667 | 417 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's accounts payable?
- Castle Biosciences (CSTL) reported accounts payable of $15.04M in Q1 2026.
- How has Castle Biosciences's accounts payable changed year-over-year?
- Castle Biosciences's accounts payable increased by 76.9% year-over-year, from $8.5M to $15.04M.
- What is the long-term trend for Castle Biosciences's accounts payable?
- Over 5 years (2020 to 2025), Castle Biosciences's accounts payable has grown at a 54.9% compound annual growth rate (CAGR), from $2.1M to $18.71M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Castle Biosciences's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude